Horgan Rebecca, Bitas Christiana, Abuhamad Alfred
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA.
Am J Obstet Gynecol MFM. 2023 Mar;5(3):100838. doi: 10.1016/j.ajogmf.2022.100838. Epub 2022 Dec 9.
This study reviewed the literature regarding the diagnosis, antepartum surveillance, and timing of delivery of pregnancies complicated by intrahepatic cholestasis of pregnancy, comparing the guidelines published by the Society for Maternal-Fetal Medicine in February 2021 and those published by the Royal College of Obstetricians and Gynaecologists in the United Kingdom in June 2022. Several key differences exist in the clinical guidelines between the 2 organizations. With regard to the diagnosis of intrahepatic cholestasis of pregnancy, the Society for Maternal-Fetal Medicine considers any elevation in bile acids above the upper limit of normal in the setting of maternal pruritus diagnostic of intrahepatic cholestasis of pregnancy, whereas the Royal College of Obstetricians and Gynaecologists requires a pregnancy-specific elevated bile acid level of ≥19 mmol/L for diagnosis. Regarding the treatment of intrahepatic cholestasis of pregnancy, the Society for Maternal-Fetal Medicine recommends ursodeoxycholic acid as the first-line treatment of maternal symptoms. In contrast, the Royal College of Obstetricians and Gynaecologists specifically recommends against the routine use of ursodeoxycholic acid for intrahepatic cholestasis of pregnancy because of a lack of evidence regarding both maternal and fetal benefit. The Society for Maternal-Fetal Medicine recommends fetal surveillance at a gestational age when abnormal fetal testing would result in delivery being performed, whereas the Royal College of Obstetricians and Gynaecologists does not recommend any fetal testing beyond fetal kick count assessment. The Society for Maternal-Fetal Medicine recommends delivery at 36 to 39 weeks' gestation for intrahepatic cholestasis of pregnancy with bile acids <100 mmol/L and delivery at 36 weeks for bile acid levels >100 mmol/L. The Royal College of Obstetricians and Gynaecologists recommends serial assessment of bile acids with delivery timing stratified between 35- and 40-weeks' gestation according to bile acid levels.
本研究回顾了关于妊娠合并肝内胆汁淤积症的诊断、产前监测及分娩时机的文献,比较了母胎医学协会于2021年2月发布的指南和英国皇家妇产科医师学院于2022年6月发布的指南。这两个组织的临床指南存在几个关键差异。关于妊娠合并肝内胆汁淤积症的诊断,母胎医学协会认为,在孕妇瘙痒的情况下,任何高于正常上限的胆汁酸升高都可诊断为妊娠合并肝内胆汁淤积症,而皇家妇产科医师学院则要求妊娠特异性胆汁酸水平≥19 mmol/L才能诊断。关于妊娠合并肝内胆汁淤积症的治疗,母胎医学协会推荐熊去氧胆酸作为缓解孕妇症状的一线治疗药物。相比之下,皇家妇产科医师学院特别建议不要常规使用熊去氧胆酸治疗妊娠合并肝内胆汁淤积症,因为缺乏关于对母体和胎儿有益的证据。母胎医学协会建议在异常胎儿检测结果会导致进行分娩的孕周进行胎儿监测,而皇家妇产科医师学院除了胎动计数评估外,不建议进行任何其他胎儿检测。母胎医学协会建议,胆汁酸<100 mmol/L的妊娠合并肝内胆汁淤积症患者在妊娠36至39周时分娩,胆汁酸水平>100 mmol/L的患者在妊娠36周时分娩。皇家妇产科医师学院建议根据胆汁酸水平对胆汁酸进行系列评估,分娩时间在妊娠35至40周之间分层。